secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001438533-24-000007
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere and CSL Vifor receive CHMP positive opinion for sparsentan in IgAN in EU
--------------------------------------------------------------------------------

- EMA CHMP recommended conditional marketing authorization for sparsentan for primary IgAN with proteinuria >1.0 g/day.
- Positive opinion based on Phase 3 PROTECT Study results; EC final decision pending.
- If approved, sparsentan would get CMA in all EU member states plus Iceland, Liechtenstein, Norway.
- Already marketed in US as FILSPARI under accelerated approval for proteinuria reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/0001438533-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/tvtx-20240223.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer